Eagle Pharmaceuticals Announces Pricing of Initial Public Offering

Tuesday, February 11, 2014 11:39 pm EST



Public Company Information:


WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--EAGLE PHARMACEUTICALS, INC. (“EAGLE”) (NASDAQ:EGRX) announced today the pricing of its initial public offering of 3,350,000 shares of common stock at a price to the public of $15.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol “EGRX” on February 12, 2014. Eagle is offering all of the shares of common stock. Eagle has also granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of common stock. The offering is expected to close on February 18, 2014, subject to customary closing conditions.

Piper Jaffray & Co. and William Blair & Company, L.L.C. are acting as joint book-running managers. Cantor Fitzgerald & Co. is acting as co-manager.

The Securities and Exchange Commission declared effective a registration statement relating to these securities on February 11, 2014. The offering is being made only by means of a prospectus. A copy of the prospectus relating to the offering may be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, Suite 1000, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com, or from William Blair & Company, L.L.C., 222 W. Adams St., Chicago, IL 60606, or by email at prospectus@williamblair.com or by telephone at (800) 621-0687.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Eagle

Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products utilizing the FDA’s 505(b)(2) regulatory pathway. The company develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products.


Eagle Pharmaceuticals, Inc.
Daniel J. O’Connor, 201-326 5300
Finance Director
Eagle Pharmaceuticals, Inc.
David E. Riggs, 201-326 5300
Chief Financial Officer

Business Wire InvestorHQsm